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Annexin A1 (AnxA1) is a candidate regulator of the epithelial- to
mesenchymal (EMT)-like phenotypic switch, a pivotal event in breast
cancer progression.We showhere that AnxA1 expression is associated
withahighly invasivebasal-likebreast cancer subtypeboth inapanelof
human breast cancer cell lines as in breast cancer patients and that
AnxA1 is functionally related to breast cancer progression. AnxA1
knockdownininvasivebasal-likebreastcancercells reducedthenumber
of spontaneous lung metastasis, whereas additional expression of
AnxA1 enhanced metastatic spread. AnxA1 promotes metastasis
formationbyenhancingTGFβ/Smadsignalingandactin reorganization,
which facilitates an EMT-like switch, thereby allowing efﬁcient cell
migration and invasion of metastatic breast cancer cells.
Annexin A1 (AnxA1) belongs to the family of calcium/phos-pholipid-binding and actin regulatory proteins (1). Using pro-
teomic analysis we have previously identiﬁed AnxA1 and its family
member AnxA2 as candidate regulators of oncogene-induced cell
morphology switch (2). During such a switch, tumor cells change
from an epithelial- to a more migratory, mesenchymal-like pheno-
type. This switch enables them to increase their motility and inva-
siveness, allowing metastasis and progression of breast cancer (3).
Despite the identiﬁcation of AnxA1 as one of several cellular pro-
teins that is differentially expressed during the progression of
tumors to more malignant states (4), a functional role for AnxA1 in
breast cancer progression andmetastasis is lacking (5, 6).Therefore,
we set out to study AnxA1 expression in different breast cancer cell
subtypes and its role andmechanism in the control of breast cancer
progression and metastasis formation.
Several different subtypes of breast carcinomas canbe identiﬁed
based on gene expression proﬁling studies (e.g., luminalA, luminal
B, normal breast-like, ErbB2-positive, and basal-like) (7, 8). These
subtypes differ in their morphology, clinical course, and response
to therapy. For example, whereas the luminal subtype is charac-
terized by its mild invasive capacity and relatively good clinical
outcome, the basal-like subtype is characterized by enhanced
invasiveness and formation of distant metastasis and, thereby, a
poor clinical outcome (7, 9). The enhanced metastatic capacity of
basal-like breast cancer (BLBC) is associated with their migratory,
mesenchymal-like phenotype (10).
Here, we show that high AnxA1 expression is associated with
the BLBC subtype in a panel of breast cancer cell lines.
Depletion of AnxA1 in BLBC cells resulted in reversal of their
migratory, mesenchymal-like phenotype, which was associated
with actin reorganization, decreased TGFβ/Smad signaling, and
a reduction in the number of spontaneous lung metastasis in
vivo. Moreover, using tissue microarrays (TMAs), we show that
AnxA1 clearly discriminates BLBC patients from other breast
cancer patients.
Results
High AnxA1 Expression in BLBC Is Associated with Their Mesenchymal-
Like Phenotype. To establish the relationship between AnxA1 ex-
pression andbreast cancer cell phenotype, a panel of humanbreast
cancer cell lines was screened for AnxA1 expression. AnxA1 was
highly expressed in cells that were characterized as mesenchymal-
like (11) and classiﬁed as cytokeratin (CK)5+/estrogen receptor
(ER)− BLBC cells (12, 13) (Fig. 1 A and B). In contrast, CK5−/
ER+ luminal-like breast cancer cells almost completely lacked
AnxA1 (Fig. 1 A and B).
To verify whether AnxA1 regulates the migratory, mesenchymal-
like phenotype of BLBC cells, AnxA1was depleted in a selection of
these cells by using either transient siRNA- or stable lentiviral
shRNA-mediated knockdown. In control cells, AnxA1 is localized
at the plasma membrane site, in the actin-rich membrane rufﬂes
(MDA-MB-231), and migratory tips (4T1), which are required for
migration, invasion, and metastasis (Fig. 1 C–E). In all selected
BLBC cells, AnxA1 knockdown resulted in a morphological switch
from a migratory, mesenchymal-like phenotype to a resting, epi-
thelium-like phenotype (Fig. 1C–E and Fig. S1A–D). This reversal
of the migratory phenotype was associated with a clear rearrange-
ment of the actin cytoskeletal network; actin-rich rufﬂes were lost
and long F-actin stress ﬁbers were obtained (Fig. 1 D and E).
Moreover, AnxA1 knockdown induced the formation of β-catenin-
containing cell-cell junctions in all cells, which were most clearly
visible in the highly motile MTLn3 cells (Fig. S1 C and D). In
addition, AnxA1 knockdown signiﬁcantly reduced the migration
distance and random cell migration speed of siAnxA1MTLn3 cells
(Fig. S1 E–G and Movies S1, S2, and S3). The AnxA1 knockdown-
induced epithelium-likemorphologyofMTLn3 cellswas rescuedby
ectopic expression of AnxA1 (Fig. S1 C and D). These combined
data demonstrate that AnxA1 is involved in an EMT-like switch,
facilitating cell migration in vitro.
Knockdown of AnxA1in BLBC Cells Impairs TGF Signaling. The switch
fromanepithelial to amesenchymal-likephenotype is, amongother
pathways, regulatedbyTGFβ signaling (14).BecauseAnxA1knock-
down induces a morphological switch from a mesenchymal- to an
epithelium-like phenotype in different BLBC cells, we determined
its inﬂuence on TGFβ signaling. TGFβ induces clustering of
TGFβRI and II and, subsequently, phosphorylation of Smad2.
AnxA1 knockdown in MDA-MB-231 cells impaired Smad2 phos-
phorylation in response to TGFβ exposure (Fig. 2 A and B). Smad2
phosphorylation is a trigger forSmad2 to formacomplexwithSmad4,
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resulting in nuclear translocation of the Smad2/Smad4 complex and
subsequent gene transcription. AnxA1 knockdown MDA-MB-231
cells exposed toTGFshow lessnuclear translocationofSmad4 (Fig. 2
C and D). In addition, knockdown of AnxA1 in MDA-MB-231,
BT549, and MTLn3 cells resulted in reduced activity of TGFβ/
Smad3/Smad4-driven (CAGA)12-luciferase transcriptional reporter
activity (Fig. 2 E–G), indicating that AnxA1 is also involved in the
regulation of TGFβ/Smad3 response. Furthermore, the TGFβ-type I
receptor inhibitor SB-431542 (15) reduced (CAGA)12-luciferase
activity in MTLn3 cells both in the absence and presence of TGFβ
(Fig. S2A), and reversed themesenchymal-like phenotype (Fig. S2B)
similar to the morphological switch observed in AnxA1 knockdown
cells (Fig. S1 C and D). Moreover, TGFβ alone enhanced cell scat-
tering (Fig. S2B).Altogether, the data suggest thatAnxA1 is involved
in TGFβ-induced EMT-like switch.
Expression of AnxA1 Induces an EMT-Like Switch by Activation of the
TGFβ Pathway. Next, we considered whether AnxA1 expression in
a typical luminal-like breast cancer cell line that has low AnxA1
expression, would induce a scattered phenotype. Indeed, AnxA1
expression in luminal-like MCF7 cells resulted in increased cell
scattering (Fig. 3 A and B), which was associated with a disruption
of F-actin stress ﬁbers, an increase in actin-rich rufﬂes, and a
decrease in β-catenin-containing cell-cell junctions (Fig. 3A andB
and Fig. S2E). MCF7 cells expressing AnxA1 showed increased
TGFβ-induced Smad3/Smad4 transcriptional reporter activity,
explaining the increase in cell scattering (Fig. 3C). Increased
TGFβ-induced Smad3/Smad4 transcriptional reporter activity was
also observed in epithelium-like cell lines BT474 and T47D cells
(Fig. S2 C and D, respectively) The AnxA1-induced increase in
Smad3/Smad4 transcriptional response was inhibited by the TGFβ
type I receptor inhibitor SB-431542, suggesting that AnxA1 might
affect an autocrine signaling loop of TGFβ−induced receptor
activation (Fig. 3C). This notion was supported by the observation
that AnxA1-expressing MCF7 cells exposed to the SB-431542
showed a morphological change from a mesenchymal-like to an
epithelial phenotype (Fig. 3 D and E). Overall, our data strongly
support the importance of AnxA1 in the regulation of a morpho-
logical switch from a resting epithelium-like to a migratory phe-
notype through regulation of the TGFβ/Smad pathway.
Fig. 1. AnxA1 expression in BLBC is associated with their migratory pheno-
type. (A) A panel of human breast cancer cell lines was analyzed for AnxA1
mRNA levels. (B) Western blot analysis of AnxA1 protein levels in luminal-like
(BT474, MCF7, T47D) versus basal-like (HBL100, BT549, MDA-MB-231) human
breast cancer cell lines andbasal-likemouse 4T1and ratMTLn3 cells. (C) AnxA1
localization was determined in MDA-MB-231 cells by staining for AnxA1
(green) and actin (red). (D and E) Knockdown inMDA-MB-231 (D) and 4T1 cells
(E) was established by using lenti-viral shRNA speciﬁc for turbo-GFP (Control
shRNA) and AnxA1 (AnxA1 shRNA1). Cells were plated on collagen and sub-
sequently ﬁxated and stained for AnxA1 and F-actin (rhodamin-phalloidin).
(Scale bars: 20 μm.)Data are representative of three independent experiments.
Fig. 2. Knockdown of AnxA1in BLBC cells impairs TGF signaling. (A) Stable
MDA-MB-231knock-downcellswereexposed toTGFβ1 (0.5ng/mL) for indicated
time periods. Phosphorylation of Smad2, Smad2 and Smad4 expression was
determined byWestern blotting. (B) Quantiﬁcation of Smad2 phosphorylation.
TranslocationofSmad4wasdeterminedbySmad4stainingofMDA-MB-231cells
exposed to TGFβ1 for 30 min (C) and quantiﬁcation of nuclear intensity (D).
TGFβ1-induced transcription was determined by transient transfection of
(CAGA)12-luciferase in AnxA1 depletedMDA-MB-231 (E), BT549 (F), andMTLn3
cells (G). After transfection, cells were exposed to TGFβ1 (0.5 ng/mL) for 24 h.
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Knockdown of AnxA1 Decreases the Metastatic Potential of Highly
Aggressive 4T1 Cells. Next, we determined whether AnxA1 deple-
tion from highly invasive breast cancer cells can reduce metastasis
formation in vivo. Therefore, the well characterized invasive
breast cancer cell line 4T1was used, which is able to spontaneously
metastasize from a primary tumor in vivo (16). To establishAnxA1
depletion in 4T1 cells, two independent lenti-viral shRNA were
used (Fig. 4A). The control cell line expresses a shRNA sequence
against turbo-GFP. Cells were injected into themammary fat pads
of 12-week-old Rag2−/−/γc−/−mice. Knockdown of AnxA1 had no
effect on primary tumor growth (Fig. 4B and Fig. S3B). Mice were
killed at day 22, and histological evaluation of the primary tumor
conﬁrmed decreased expression of AnxA1 in tumors derived from
AnxA1 shRNA cells (Fig. S3A). Lungs of animals injected with
control 4T1 contained >130 surface metastases (Fig. 4 C–E),
whereas animals injected with either AnxA1 knockdown 4T1
contained on average ≈30 surface metastases (Fig. 4C–E). In line
with our ﬁndings in Rag2−/−/γc−/− mice, AnxA1 knockdown did
not affect primary tumor growth, but signiﬁcantly reduced the
number of lung metastases in syngenic Balb/C mice (Fig. S3 B and
C). In addition, metastasis formation of AnxA1 knockdown
MTLn3 cells was markedly reduced (Fig. S3 D and E).
The reduction in metastasis formation by AnxA1 depletion was
associated with reduced TGFβ/Smad signaling. Smad2 phos-
phorylation in primary tumors was reduced as well as the nuclear
levels of Smad4 (Fig. 4 F and G, respectively). Our in vivo data
indicate that the morphological changes induced by AnxA1
knockdown are linked to a decrease in breast cancer progression
via the effect on TGFβ/Smad signaling.
AnxA1 Distinguishes Basal-Like Breast Cancer Patients from Others.
To verify our ﬁnding thatAnxA1 is expressed in a speciﬁc subset of
breast cancer cells, human TMA containing tissues of 452 breast
Fig. 3. AnxA1 induced cell scattering in luminal-like MCF7 cells through
TGFβ pathway activation. (A) MCF7 cells were transfected with GFP or GFP-
AnxA1. Cells were plated on collagen for 24 h and subsequently ﬁxated and
stained for AnxA1. Cells were costained with phosphoY118-paxillin to visu-
alize all cells within the frame. (B) The number of scattered cells was
determined for the GFP positive cells. (C) Cotransfection of (CAGA)12-luc and
GFP-AnxA1 was performed and cells were exposed to TGFβ and/or SB-431542
and, thereafter, luciferase activity was measured. (D) MCF7 cells expressing
GFP-AnxA1 were exposed to SB-431542 and stained for F-actin. (E) Cell
scattering induced by AnxA1 expression was reduced by SB-431542. (Scale
bars: 20 μm.) Data are representative of three independent experiments.
*, P < 0.05; **, P < 0.01.
Fig. 4. Knockdown of AnxA1 decreases the metastatic potential of highly
invasive 4T1 cells via decreased TGFβ signaling. (A) Mouse breast cancer 4T1
cells were transduced with lenti-viral shRNA speciﬁc for turbo-GFP (control
shRNA) and two sequences for AnxA1 (AnxA1 shRNA1 and 2). AnxA1
knockdown was determined by Western blot analysis. (B) AnxA2 levels were
included in the analysis to show speciﬁcity of the shRNAs. Equal loading was
conﬁrmed by tubulin staining. AnxA1 shRNA1 (n = 6), AnxA1 shRNA2 (n = 6),
and control shRNA (n = 7) 4T1 cells were injected into the mammary fat pad
of 12-week-old Rag2 −/− /γc −/− mice. Tumor volume was determined as
described in Materials and Methods. (C) At 22 days after injection, the mice
were killed and lungs were isolated. Lung sections were stained for H&E
to visualize lung metastases. Lungs were inoculated with ink as described
under Materials and Methods (D) and surface metastases were quantiﬁed
(E). ***, P < 0.001. Primary tumors were stained for p-Smad2 and Smad4
using Nova-Red staining and quantiﬁed for equal expression of Smad2 (F)
and Smad4 (G) by using Western blotting. * P < 0.05, ** P < 0.01.
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cancer patients were analyzed. In contrast to normal breast tissue
where AnxA1 is localized in both the luminal and myoepithelial
cell layer (Fig. 5A), in premalignant breast tissue, AnxA1 was
mainly expressed in the myoepithelial cell layer, where it localized
both in the cytosol as well as the nucleus (Fig. 5Ba). In breast
cancers, the majority of the tumor tissue showed negative (Fig. 5B
a and b; n = 323) or low expression (n = 85) of AnxA1, whereas
≈10% showed high expression of AnxA1 (Fig. 5B c and d; n=44).
The AnxA1-negative/low cases included both ductal carcinoma in
situ (DCIS) as well as invasive ductal carcinoma (IDC), whereas
AnxA1-positive tumors includedmainly IDC (Fig. 5B andFig. S4).
Further analysis revealed that AnxA1 expression correlated with
high pathologic tumor grade (P < 0.001; Fig. S5A and Table S1).
In addition to AnxA1, TMAs were stained and scored for
AnxA2 and six markers currently used for the identiﬁcation of
speciﬁc subgroups of breast tumors [e.g., human epidermal growth
factor receptor 2 (HER2), the hormonal receptors ER and PR
(progesterone receptor), basal and luminal CK5 and CK8,
respectively, and p53]. Statistical analysis of the expression data
conﬁrmed an overall signiﬁcant correlation between AnxA1
expression and proteins associated with BLBC (e.g., p53high,
CK5high, ERlow, CK8low) (Fig. S5 B–E and Tables S2, S3, S4, and
S5), suggesting that AnxA1 is also predictive for BLBC in breast
cancer patients.
Unsupervised hierarchical clustering of the protein expression
data subdivided all breast cancers into four clusters: a small
undeﬁned CK5+/8+/ER+ group (1; ≈5%), ER+/luminal-like (2;
≈60%), HER2-positive (3; ≈20%), and triple negative (ER−/
PR−/HER2−) (4; ≈15%) (Fig. 5C and Fig. S5). AnxA1 was
almost exclusively expressed in the small CK5+/8+/ER+ sub-
group (1) and triple negative breast cancer subgroup (4),
whereas its close family member AnxA2 was expressed in all four
clusters. Moreover, a clear correlation was found between p53
and AnxA1 expression within the triple negative subgroup.
Although, triple negative breast cancers are described as a het-
erogeneous group of cancers, the majority display a basal-like
phenotype (17). CK5 expression, either in association with the
lack of ER/PR/HER2 or alone (17, 18), is often used to deﬁne
the poor prognosis BLBC subtype. Our cluster analysis revealed
that AnxA1 clusters directly with CK5, a marker for the BLBC
subtype (Fig. 5C). Moreover, our unsupervised hierarchical
clustering showed that CK5 is not solely expressed in the triple
negative group, but also in the luminal-like and HER2+ tumor
samples. In contrast, AnxA1 is almost exclusively expressed in
the triple negative subgroup [marker prediction of a tumor to be
in the triple negative subgroup versus any other subgroup (Odd
Ratios; 95% conﬁdence interval)]: CK5 2.2 (1.2–4.2), P = 0.01,
and AnxA1 10.5 (4.9–22.2), P < 0.0001. Because of the small
number of AnxA1-positive patients, we were unable to sig-
niﬁcantly correlate AnxA1 protein expression to recurrence and
relapse-free survival, yet a clear trend was observed between
AnxA1 protein expression and recurrence. In addition, within
the speciﬁc gene signature for poor prognosis deﬁned by van de
Vijver et al. (19), AnxA1 gene expression was signiﬁcantly higher
in basal-like than in the other tumor subtypes (P < 0.001; Table
S6). Altogether our data shows that AnxA1 is associated with the
BLBC subtype and functionally involved in BLBC progression
and metastasis formation by regulating TGFβ-signaling and actin
cytoskeletal reorganization.
Discussion
BLBCs represent <10% of all breast cancers and show enhanced
invasiveness and metastatic potential (9). Given the poor disease
prognosis associated with BLBC, improving methods to accu-
rately identify BLBC in the clinic as well as better mechanistic
understanding of the molecular programs that deﬁne the meta-
static potential are essential. Our data demonstrated that BLBCs
express high levels of AnxA1 and that AnxA1 is important
for their capacity to metastasize because it facilitates a migra-
tory phenotype.
Depletion of AnxA1 in a panel of BLBC cells resulted in
reversal of their migratory phenotype and inhibition of lung
metastasis formation. We show that AnxA1 expression controls
the aggressive behavior of BLBC cells via a TGFβ-mediated
EMT-like switch, thereby allowing a migratory phenotype of breast
cancer cells and metastasis formation. AnxA1 knockdown sup-
pressed TGFβ-induced Smad2 phosphorylation, Smad4 nuclear
translocation and Smad3/Smad4-driven transcriptional reporter
activity. Moreover, primary tumors with AnxA1 knockdown had a
reduced Smad2 phosphorylation and Smad4 nuclear localization.
A biological role of AnxA1 is not restricted to BLBC-like tumor
cells. Despite the fact that luminal-like breast tumor cells do not
express AnxA1, ectopic expression of AnxA1 in luminal-like
MCF7 cells resulted in a clear EMT-like switch. Moreover,
enhanced TGFβ signaling now occurred in these cells. Therefore,
it is likely that such a role of AnxA1 is also relevant in other
aggressive tumor cell types. Our data on the role of TGFβ in the
metastasis formation are in conjunction with the study of Deckers
et al. (20) that demonstrated that TGFβ signaling via Smad4 is
required for TGFβ-induced EMT and bone metastasis formation
of NMuMG and MDA-MB-231 cells respectively. Moreover,
TGFβ in the breast tumor microenvironment was shown to prime
cancer cells for metastasis to the lungs (21), and TGFβ antagonists
reverse the migratory phenotype that is characteristic of BLBC
cells, thereby affecting the progression of BLBC (22). We antici-
pate that AnxA1 is a central player in TGFβ-signaling dependent
cancer progression.
Fig. 5. AnxA1 discriminates BLBCs from other subtypes. (A) Normal breast
tissue was stained for AnxA1. (B) Human breast cancer tissues (TMA of 452
patients) were screened for AnxA1, AnxA2, and six clinical markers CK5,
CK8, ER, PR, HER2, and p53. Representative images are shown for pre-
malignant breast tissue (a; note the AnxA1 positive myoepithelial cells
pointed by an arrow), AnxA1 negative ductal carcinoma in situ (DCIS) (b),
and AnxA1 positive, invasive ductal carcinoma (IDC) (c and d). Only those
breast carcinomas where staining for all of the eight immunohistochemical
markers was successful (n = 295) were included for hierarchical unsupervised
cluster analysis (B) and tumors were divided luminal-like, HER2+, and triple
negative groups (C).
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Members of the annexin family have been shown to be
involved in endocytosis (23–27). Although AnxA1 was enriched
in membrane fractions containing early endosomes (28), it re-
mains unclear how AnxA1 is involved in endocytosis and, in
particular, endocytosis of TGFβ-receptors. Inhibition of TGFβ
receptor endocytosis results in decreased Smad2 phosphorylation
and Smad-mediated gene transcription (29–31). We propose that
AnxA1 may inﬂuence TGFβ signaling by interfering with TGFβ-
receptor endocytosis.
In addition to its direct effect on endocytosis, AnxA1 may
inﬂuence internalization of TGFβ receptors indirectly via regu-
lation of the actin cytoskeleton like has been described for AnxA2
(27). Decreased actin cytoskeletal dynamics as observed in our
AnxA1 knockdown cells might stiffen the cell membrane, thereby
impeding TGFβ-receptor internalization. Compared with other
actin-regulatory proteins, AnxA1 has the unique property to bind
both phospholipids at the plasma membrane and F-actin, thereby
stabilizing and/or regulating membrane–actin interactions (32).
To deﬁne BLBCs in the clinic, pathologists often use immu-
nohistochemical staining of the classical marker CK5. However,
we and others show that CK5 is also expressed in luminal-like and
HER2 breast cancers, suggesting that the sole reliance on CK5
could result in false-positive characterization (Fig. 5) (33). Our
TMA data analysis revealed a signiﬁcant correlation between
high AnxA1 protein expression and the BLBC subtype without
any high expression levels in the luminal-like or HER2 breast
cancers (Fig. 5). Moreover, AnxA1 gene expression was sig-
niﬁcantly higher in basal-like than in the other tumor subtypes in
the poor prognosis gene signature of van de Vijver et al. (19) (P <
0.001; Table S6), and AnxA1 was found to be overexpressed in
two gene signatures described to distinguish BLBC from other
subtypes (7, 34). Therefore, we propose AnxA1 as an additional
marker to improve diagnostics to better discriminate BLBCs from
other subtypes in the clinic. Currently, we are collecting patient
material and data for a larger cohort study performed by several
independent pathologists (in total >2,000 patients), which will
validate the potential of AnxA1 as an ofﬁcial marker for improved
identiﬁcation of the highly aggressive BLBC subtype and its
association with a poor prognosis.
Taken together, our data show that AnxA1 is functionally
involved in BLBC progression and metastasis formation and is
able to regulate TGFβ signaling and actin cytoskeletal reorgan-
ization. We propose AnxA1 as an additional marker to improve
diagnostics to better discriminate BLBCs from other subtypes in
the clinic.
Materials and Methods
Cell Line Maintenance and Treatments. The breast cancer cell lines used for
real-time PCR analysis in this study were cultured and characterized for
morphology (e.g., epithelial vs. mesenchymal) and E-cadherin promoter
methylation as described (11). MTLn3 rat mammary adenocarcinoma cells
(35) were cultured as described (36). The 4T1 mouse breast cancer cell line
was obtained from American Type Culture Collection (CRL-2539) and cul-
tured in RPMI 1640 Medium (Gibco) supplemented with 10% FBS.
RNA Isolation and Real-Time PCR. Cell culture of the panel of breast cancer cell
lines described in Fig. 1A, RNA isolation, and RT-PCR was performed as
described (11).
Expression and Knockdown of AnxA1. For preparation of stable shRNA cell
lines, 4T1, MDA-MB-231, and BT549 cells were transduced by using lenti-viral
shRNA vectors [Sigma-Aldrich, kindly provided by Rob Hoeben, Leiden Uni-
versity Medical Center (LUMC)]. See SI Materials and Methods for sequences.
Cells were selected by using puromycin. For transient knockdown of AnxA1
Dharmacon Smartpool siRNAs against GFP (control) or AnxA1 (rat and
human) were used. Transfections were performed according to the manu-
facturer’s protocol by using Dharmafect reagent 2 (MTLn3) and 4 (MDA-MB-
231, HBL-100) (Dharmacon).
In Vivo Tumor Growth andMetastasis Formation. Tumor cells (1 × 105 4T1) in 0.1
mL of PBS were injected into the fat pad of 12-week old female Rag2−/−/γc−/−
or BALB/c mice. Size of the primary tumors was measured by using calipers.
Horizontal (h) and vertical (v) diameters were determined and tumor volume
(V) was calculated: V = 4/3π{1/2[√(h x v)]3}. Surface lung metastases were
counted for each animal using ink injected lungs (n = 5–7 per group). See SI
Materials and Methods for details on breeding and procedures. All animal
experiments were approved by the local ethical committee.
Antibodies. See SI Materials and Methods.
Immunohistochemistry. Tumors and lungs were embedded in parafﬁn and
sectioned (4 μm) onto 3-aminopropyltriethoxysilane-coated slides. After
deparafﬁnization, the tumor and lung sections were stained for H&E and
lungs were examined for lung metastasis formation. Parafﬁn sections were
deparafﬁnized, followed by antigen retrieval in citrate buffer, incubation
with primary (phosphoSer465/467-Smad2 or Smad4) and biotynilated sec-
ondary antibodies, and a short incubation with Nova-Red. The sections were
counterstained with hematoxylin.
Western Blot Analysis. Cells were harvested as described (37). See SI Materials
and Methods for details on antibodies.
Immunoﬂuorescence and Image Analysis. Immunoﬂuorescence was performed
as described (37). See SI Materials and Methods for details on antibodies.
Luciferase Assays. Cells cultured in 48-well plates were transfected with
(CAGA)12-transcriptional luciferase (38) and renilla reporter constructs by
using Lipofectamine Plus reagent (Invitrogen). The following day, cells were
serum-starved and exposed to TGFβ1 (24 h); thereafter, cells were lysed and
luciferase activity was measured by using the dual-luciferase reporter assay
system (Promega).
Patient Selection and Study Design. Schmidt et al. (39) conducted a retro-
spective cohort study of breast cancer patients. This cohort includes women
who received surgery for invasive breast cancer in LUMC and two regional
hospitals in Leiden between 1970 and 1995 (40). The study received approval
of the Medical Ethical Committee of the LUMC. The TMA represented 518
cases of breast carcinoma; 66 cases were not analyzed for technical reasons.
TMA. Tumor characteristics were all derived from a review of slides stained
with H&E and from TMAs including three punches per tumor. Tumor grad-
ing, according to the Bloom-Richardson method (41) and tumor morphology
typing, was performed as described (39). Immunohistochemical staining of
the tissue arrays for AnxA1 was performed at the Pathology Department of
the LUMC according to the protocol described in Baelde et al. (42). Evalua-
tion of AnxA1, AnxA2, Src, CK5, and CK8 expression levels was performed
independently by two scientists and a pathologist (M.H.v.M., M.d.G., and
V.T.S.). The intensity of the staining was scored on a 0–3 scale. Evaluation of
ER, PR, p53, and Her2 was performed as described (39). Only those breast
carcinomas where staining for all of the eight immunohistochemical markers
was successful (n = 295) were included for hierarchical unsupervised cluster
analysis (UPGMA method; assuming Euclidian distances between scores) by
using the GEPAS package.
Statistical Analysis in Vitro and in Vivo. TMA statistical analysis was done by
using Statistical Package for the Social Sciences SPSS 15.0 and differences in
proportions were tested by Pearson χ2. For in vitro and in vivo animal studies,
Student’s t test was used to determine whether there was a signiﬁcant
difference between two means (P < 0.05). When multiple means were
compared, signiﬁcance was determined by one-way analysis of variance
(ANOVA; P < 0.05). Signiﬁcant differences are marked in the graphs.
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